Spots Global Cancer Trial Database for vemurafenib
Every month we try and update this database with for vemurafenib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation | NCT01959633 | Melanoma | Vemurafenib Peg-interferon Cobimetinib | 18 Years - | Fondazione Melanoma Onlus | |
| A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma | NCT01910181 | Malignant Melan... | Vemurafenib | 18 Years - | Hoffmann-La Roche | |
| Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies | NCT02441465 | Malignant Melan... | Vemurafenib 14C-Labeled Vem... | 18 Years - | Hoffmann-La Roche | |
| Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) | NCT05233332 | CRC | HL-085 Vemurafenib | 18 Years - 80 Years | Shanghai Kechow Pharma, Inc. | |
| Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients | NCT03224208 | Melanoma Melanoma (Skin) Melanoma Stage | Vemurafenib Cobimetinib | 18 Years - | Fondazione Melanoma Onlus | |
| A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State | NCT02608034 | Metastatic Mela... | Itraconazole Rifampin Vemurafenib | 18 Years - | Genentech, Inc. | |
| A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma | NCT01765569 | Malignant Melan... | Digoxin Vemurafenib | 18 Years - | Hoffmann-La Roche | |
| Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | NCT01596140 | Advanced Cancer Solid Tumor | Vemurafenib Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC | NCT02303951 | Malignant Melan... | Vemurafenib Cobimetinib Atezolizumab | 18 Years - | University Hospital Tuebingen | |
| Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations | NCT01531361 | Advanced Malign... BRAF Gene Mutat... Metastatic Mali... Recurrent Malig... Refractory Mali... | Crizotinib Laboratory Biom... Pharmacological... Sorafenib Tosyl... Vemurafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma | NCT01754376 | Melanoma | Aldesleukin Vemurafenib | 18 Years - | Massachusetts General Hospital | |
| Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 | NCT02456701 | Thyroid Cancer | KTN3379 vemurafenib | 18 Years - | Celldex Therapeutics | |
| Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma | NCT01943422 | Melanoma | High-dose Inter... Vemurafenib | 18 Years - | University of Pittsburgh | |
| BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations | NCT01519323 | Malignant Melan... | vemurafenib | 12 Years - 17 Years | Hoffmann-La Roche | |
| Radiation Use During Vemurafenib Treatment | NCT01843738 | BRAFV600 Mutati... Stage IV Melano... | Radiation thera... Vemurafenib | 18 Years - | University of Utah | |
| A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU]) | NCT03139513 | Melanoma | Cobimetinib Vemurafenib | 18 Years - | Hoffmann-La Roche | |
| Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor | NCT01603212 | Melanoma | Vemurafenib IL-2 Interferon Alph... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) | NCT01006980 | Malignant Melan... | Vemurafenib Dacarbazine | 18 Years - | Hoffmann-La Roche | |
| Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer | NCT01791309 | Metastatic Colo... | combination pan... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II | NCT05525858 | Solid Tumor Advanced Solid ... Metastatic Canc... | Alectinib Atezolizumab Erlotinib Trastuzumab + P... Trastuzumab emt... Vemurafenib Bevacizumab + E... Entrectinib Pralsetinib | 19 Years - | Seoul National University Bundang Hospital | |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | NCT03220035 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor | Laboratory Biom... Vemurafenib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Radiation Use During Vemurafenib Treatment | NCT01843738 | BRAFV600 Mutati... Stage IV Melano... | Radiation thera... Vemurafenib | 18 Years - | University of Utah | |
| Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma | NCT03224767 | BRAF V600E Muta... Papillary Crani... | Vemurafenib Cobimetinib Laboratory Biom... Quality-of-Life... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 | NCT02456701 | Thyroid Cancer | KTN3379 vemurafenib | 18 Years - | Celldex Therapeutics | |
| S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer | NCT02164916 | Colorectal Canc... | cetuximab irinotecan hydr... vemurafenib | 18 Years - | SWOG Cancer Research Network | |
| Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | NCT02902029 | Malignant Melan... | Vemurafenib Cobimetinib Atezolizumab | 18 Years - | University Hospital, Essen | |
| Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity | NCT02314481 | Non-small Cell ... | MPDL3280A Vemurafenib Alectinib Trastuzumab emt... | 18 Years - | University College, London | |
| Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | NCT01596140 | Advanced Cancer Solid Tumor | Vemurafenib Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation | NCT01959633 | Melanoma | Vemurafenib Peg-interferon Cobimetinib | 18 Years - | Fondazione Melanoma Onlus | |
| Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation | NCT01474551 | Melanoma | vemurafenib | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma | NCT01495988 | Melanoma Metastatic Mela... | Vemurafenib Bevacizumab Cobimetinib | 18 Years - | Melanoma Research Foundation Breakthrough Consortium | |
| Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. | NCT01636908 | Cancer Advanced Solid ... | Sunitinib Sorafenib Erlotinib Everolimus Lapatinib Dasatinib Pazopanib Vemurafenib tumor biopsy skin biopsy (op... | 18 Years - | Amsterdam UMC, location VUmc | |
| A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | NCT01849666 | Malignant Melan... | phenprocoumon vemurafenib | 18 Years - 70 Years | Hoffmann-La Roche | |
| Vemurafenib and White Blood Cell Therapy for Advanced Melanoma | NCT01585415 | Metastatic Canc... Melanoma | Vemurafenib Young TIL Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - 66 Years | National Institutes of Health Clinical Center (CC) | |
| Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma | NCT01657591 | Melanoma | XL888 Vemurafenib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Vemurafenib and TIL Therapy for Metastatic Melanoma | NCT02354690 | Metastatic Mela... | Vemurafenib Lymphodepleting... TIL infusion Interleukin-2 | 18 Years - 70 Years | Herlev Hospital | |
| Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases | NCT01781026 | Melanoma | Vemurafenib | 18 Years - | Yale University | |
| A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia | NCT03410875 | Hairy Cell Leuk... Leukemia Leukemia, Hairy... | Vemurafenib Obinutuzumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma | NCT03224767 | BRAF V600E Muta... Papillary Crani... | Vemurafenib Cobimetinib Laboratory Biom... Quality-of-Life... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation | NCT03781219 | Solid Tumor | HL-085 Vemurafenib | 18 Years - 70 Years | Shanghai Kechow Pharma, Inc. | |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
| A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants | NCT01767623 | Neoplasms | Vemurafenib | 18 Years - | Hoffmann-La Roche | |
| Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases | NCT02036086 | Melanoma | Vemurafenib Cobimetinib | 18 Years - | Sunnybrook Health Sciences Centre | |
| Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases | NCT03430947 | Malignant Melan... BRAF V600 Mutat... Brain Metastase... | Vemurafenib Cobimetinib | 18 Years - | Technische Universität Dresden | |
| A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia | NCT03410875 | Hairy Cell Leuk... Leukemia Leukemia, Hairy... | Vemurafenib Obinutuzumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer | NCT02164916 | Colorectal Canc... | cetuximab irinotecan hydr... vemurafenib | 18 Years - | SWOG Cancer Research Network | |
| A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma | NCT02050321 | Malignant Melan... | Acitretin Vemurafenib | 18 Years - | University of Arizona | |
| Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma | NCT01943422 | Melanoma | High-dose Inter... Vemurafenib | 18 Years - | University of Pittsburgh | |
| The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma | NCT01942993 | Melanoma | Vemurafenib | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases | NCT02036086 | Melanoma | Vemurafenib Cobimetinib | 18 Years - | Sunnybrook Health Sciences Centre | |
| A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases | NCT01378975 | Malignant Melan... | Vemurafenib | 18 Years - | Hoffmann-La Roche | |
| A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma | NCT02768207 | Metastatic Mela... | Cobimetinib Vemurafenib | 18 Years - | Hoffmann-La Roche | |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
| Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases | NCT02230306 | Active Melanoma... | Cobimetinib Vemurafenib | 18 Years - | University of Pittsburgh | |
| Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma | NCT01611675 | Melanoma | Vemurafenib Leflunomide | 18 Years - | Massachusetts General Hospital | |
| A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma | NCT01910181 | Malignant Melan... | Vemurafenib | 18 Years - | Hoffmann-La Roche | |
| Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib | NCT01876641 | Metastatic Mela... Melanoma BRAF-mutated Me... V600EBRAF-mutat... | Vemurafenib + C... | 18 Years - | University of Iowa | |
| Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma | NCT01659151 | Metastatic Mela... | High Dose Inter... ACT with TIL In... Vemurafenib Lymphodepletion | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma | NCT02721459 | Melanoma Skin Cancer | XL888 Vemurafenib Cobimetinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma | NCT03554083 | Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... | Atezolizumab Cobimetinib Tiragolumab Vemurafenib | 18 Years - | Mayo Clinic | |
| BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia | NCT01711632 | Hairy Cell Leuk... | Vemurafenib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | NCT03220035 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor | Laboratory Biom... Vemurafenib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients | NCT01638676 | Melanoma | Vemurafenib Metformin | 18 Years - | University of Louisville | |
| KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II | NCT05525858 | Solid Tumor Advanced Solid ... Metastatic Canc... | Alectinib Atezolizumab Erlotinib Trastuzumab + P... Trastuzumab emt... Vemurafenib Bevacizumab + E... Entrectinib Pralsetinib | 19 Years - | Seoul National University Bundang Hospital | |
| Vemurafenib and TIL Therapy for Metastatic Melanoma | NCT02354690 | Metastatic Mela... | Vemurafenib Lymphodepleting... TIL infusion Interleukin-2 | 18 Years - 70 Years | Herlev Hospital | |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. | NCT05768178 | Solid Tumor Haematological ... Melanoma Thyroid Cancer,... Ovarian Neoplas... Colorectal Neop... Laryngeal Neopl... Carcinoma, Non-... Glioma Multiple Myelom... Erdheim-Chester... Thyroid Carcino... | Vemurafenib Cobimetinib | 18 Years - | Cancer Research UK | |
| A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers | NCT01524978 | Multiple Myelom... | cetuximab vemurafenib vemurafenib | 16 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases | NCT03625141 | Metastatic Mela... | Cobimetinib Atezolizumab Vemurafenib | 18 Years - | Hoffmann-La Roche | |
| Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma | NCT01611675 | Melanoma | Vemurafenib Leflunomide | 18 Years - | Massachusetts General Hospital | |
| Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) | NCT01400451 | Melanoma | Ipilimumab (BMS... Vemurafenib | 18 Years - | Bristol-Myers Squibb | |
| Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US | NCT05260684 | Melanoma | Encorafenib Binimetinib Vemurafenib Cobimetinib Dabrafenib Trametinib | 18 Years - | Pfizer | |
| A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma | NCT01910181 | Malignant Melan... | Vemurafenib | 18 Years - | Hoffmann-La Roche | |
| BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations | NCT01519323 | Malignant Melan... | vemurafenib | 12 Years - 17 Years | Hoffmann-La Roche | |
| Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | NCT01787500 | BRAF NP_004324.... KRAS wt Allele Metastatic Mali... Stage IV Colore... Stage IVA Color... Stage IVB Color... Unresectable So... | Cetuximab Irinotecan Hydr... Laboratory Biom... Pharmacological... Vemurafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | NCT03181100 | Metastatic Thyr... Poorly Differen... Stage IVA Thyro... Stage IVB Thyro... Stage IVC Thyro... Thyroid Gland A... Unresectable Th... | Atezolizumab Bevacizumab Cobimetinib Nab-paclitaxel Paclitaxel Vemurafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Vemurafenib, Carboplatin, and Paclitaxel | NCT01636622 | Advanced Cancer... | Vemurafenib Carboplatin Paclitaxel | 12 Years - | M.D. Anderson Cancer Center | |
| Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma | NCT01616199 | Advanced BRAF-m... | PX-866 vemurafenib | 18 Years - | Seagen Inc. | |
| A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | NCT01656642 | Malignant Melan... | Atezolizumab Cobimetinib Vemurafenib | 18 Years - | Genentech, Inc. | |
| Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma | NCT02427893 | Melanoma | Cobimetinib Vemurafenib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study | NCT02052193 | Metastatic Mela... | Dabrafenib Vemurafenib | 18 Years - | University Hospital Tuebingen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
